Clinically, our findings surpass previous observational associations between endothelial dysfunction and DN [38, 39] by proposing Slc3a2 as a functional biomarker and fludarabine as a targeted therapy. The gene discussed is SLC3A2; the disease is liver dysplastic nodule.